中医药分阶段结合化疗治疗晚期非小细胞肺癌的临床研究

目的观察中医药分阶段结合化疗治疗Ⅲ、Ⅳ期非小细胞肺癌的临床疗效。方法采用前瞻性、多中心、随机、对照的临床研究方法，将纳入的病例116例分为治疗组60例和对照组56例。对照组只予化疗单独治疗；治疗组行化疗联合中医药治疗，化疗期间服用抗瘤增效方，化疗结束后服用肺岩宁方。主要观察指标为生存期、卡氏评分、主要临床症状、不良反应等。结果治疗组的中位生存期为15．57个月，高于对照组的11．17个月，差异有显著性（P〈0．01）；治疗组生活质量也高于对照组，差异有显著性（P〈0．01）；在疲劳、气短等肿瘤主要相关症状改善方面，治疗组优于对照组；不良反应观察，治疗组出现白细胞减少症、恶心呕吐等消化道反应较对照组少，差异有显著性（P〈0．05）。结论中医药联合化疗对于延长晚期非小细胞肺癌生存期及改善生存质量均有良好效果。

Clinical Study on Treatment of Advanced Non-small-cell Lung Cancer with Chinese Herbal Medicine in Different Stages Combined with Chemotherapy

OBJECTIVE: To observe the effect of staged Chinese herbal medicinal therapy combined with chemotherapy in treating patients with non-small-cell lung cancer (NSCLC) of stage III or IV. METHODS: Adopting prospective randomized controlled multi-centered method, the 116 patients enrolled were assigned to the treated group (n = 60) and the control group (n = 56). The control group was treated by chemotherapy alone, while the treated group treated by chemotherapy combined with Chinese herbal medicine, i.e. Kangliu Zengxiao Decoction (KLZX) was administered in the chemotherapy stage, followed with Feiyanning Decoction (FYN) in the stage after ending the chemotherapy. The survival time, Karnofsky score, main clinical symptoms and adverse reactions, etc. were observed. RESULTS: The median survival time was 15.57 months in the treated group, which was higher than that in the control group (11.17 months, P< 0.01). The improvements in tumor related symptoms such as fatigue, dyspnea, etc. in the treated group were better than those in the control group (P <0.05). In addition, adverse reactions such as leucopenia, digestive reaction (such as nausea and vomiting) in the treated group were less than those in the control group (P <0.05). CONCLUSION: Chinese herbal medicine combined with chemotherapy shows favorable effect in improving quality of life and prolonging survival time on patients with advanced NSCLC.